Shaanxi Meibang Pharmaceutical Group Past Earnings Performance
Past criteria checks 0/6
Shaanxi Meibang Pharmaceutical Group's earnings have been declining at an average annual rate of -10.5%, while the Chemicals industry saw earnings growing at 4.9% annually. Revenues have been growing at an average rate of 4.1% per year. Shaanxi Meibang Pharmaceutical Group's return on equity is 2.7%, and it has net margins of 4%.
Key information
-10.5%
Earnings growth rate
-17.3%
EPS growth rate
| Chemicals Industry Growth | 12.1% |
| Revenue growth rate | 4.1% |
| Return on equity | 2.7% |
| Net Margin | 4.0% |
| Last Earnings Update | 30 Sep 2024 |
Revenue & Expenses Breakdown
How Shaanxi Meibang Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 768 | 31 | 130 | 77 |
| 30 Jun 24 | 732 | 31 | 129 | 64 |
| 31 Mar 24 | 666 | 33 | 118 | 56 |
| 31 Dec 23 | 699 | 58 | 117 | 59 |
| 30 Sep 23 | 776 | 104 | 122 | 61 |
| 30 Jun 23 | 765 | 102 | 129 | 71 |
| 31 Mar 23 | 763 | 123 | 123 | 74 |
| 31 Dec 22 | 906 | 145 | 159 | 80 |
| 30 Sep 22 | 976 | 174 | 165 | 76 |
| 30 Jun 22 | 984 | 173 | 161 | 73 |
| 31 Mar 22 | 1,055 | 171 | 168 | 76 |
| 31 Dec 21 | 842 | 126 | 120 | 64 |
| 30 Sep 21 | 706 | 91 | 92 | 55 |
| 30 Jun 21 | 679 | 84 | 82 | 58 |
| 31 Mar 21 | 625 | 82 | 72 | 54 |
| 31 Dec 20 | 569 | 79 | 62 | 51 |
| 31 Dec 19 | 516 | 76 | 60 | 40 |
| 31 Dec 18 | 439 | 59 | 54 | 27 |
| 31 Dec 17 | 422 | 61 | 48 | 26 |
Quality Earnings: 605033 has a large one-off gain of CN¥10.7M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 605033's current net profit margins (4%) are lower than last year (13.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 605033's earnings have declined by 10.5% per year over the past 5 years.
Accelerating Growth: 605033's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 605033 had negative earnings growth (-70.4%) over the past year, making it difficult to compare to the Chemicals industry average (-5.3%).
Return on Equity
High ROE: 605033's Return on Equity (2.7%) is considered low.